Skip to content Skip to left sidebar Skip to footer

Sanofi Discontinuing Menactra

Sanofi Discontinuing Menactra

In mid-2022, Sanofi will only offer MenQuadfi as their meningococcal ACYW conjugate (MCV4) vaccine. They will discontinue the distribution of Menactra in the US.

Sites currently using Menactra, need to transition to one of the other MCV4 products available: Menveo from GSK or MenQuadfi from Sanofi. The exact timing of the transition will be determined by usage over the coming months and inventory on hand in the CDC depots to minimize vaccine wastage.

To prepare for the transition, complete the below survey to let us know which MCV4 vaccine your site plans to order moving forward.

Complete the survey.